MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 8, 2004, Pages 1081-1089

  Chen, Xiaoyuan ^a   Park, Ryan ^a   Hou, Yingping ^a   Khankaldyyan, Vazgen ^b   Gonzales Gomez, Ignacio ^b   Tohme, Michel ^a   Bading, James R ^a   Laug, Walter E ^b   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Angiogenesis; Integrin; MicroPET; PEGylation; RGD

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; EOSIN; FLUORINE 18; HEMATOXYLIN; MACROGOL DERIVATIVE; SUCCINIMIDE DERIVATIVE; SUCCINIMIDYL 4 FLUOROBENZOATE F 18; TRACER; UNCLASSIFIED DRUG;

ALKALINITY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BRAIN TUMOR; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG SYNTHESIS; FEMALE; GLIOBLASTOMA; IMAGING SYSTEM; IN VIVO STUDY; INTESTINE; ISOTOPE LABELING; KIDNEY; LIVER; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; STAINING;

EID: 3943086376     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1452-2     Document Type: Article

References (36)

1. Aldape KD, Okcu MF, Bondy ML, Wrensch M. Molecular epidemiology of glioblastoma. Cancer J 2003; 9:99-106.
2. Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, Yuan X, Bigliari A, Williams JC, Hu J, Lowenstein PR. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003; 98:71-108.
3. Armstrong TS, Gilbert MR. Glial tumors-new approaches in chemotherapy. J Neurosci Nurs 2002; 34:326-330.
4. Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin Am 2002; 12:615-626.
5. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-1336.
6. 11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol 1995; 22:783-789.
7. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-18.
8. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2003; 5:237-256.
9. Lopes MB. Angiogenesis in brain tumors. Microsc Res Tech 2003; 60:225-230.
10. Fisher MJ, Adamson PC. Anti-angiogenic agents for the treatment of brain tumors. Neuroimaging Clin Am 2002; 12:477-499.
11. Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol 2003; 13:52-61.
12. Mikkelsen T. Cytostatic agents in the management of malignant gliomas. Cancer Control 1998; 5:150-162.
13. v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002; 98:690-697.
14. v-integrin antagonist. Neurosurgery 2001; 48:151-157.
15. 3-targeted magnetic resonance imaging. Nat Med 1998; 4:623-626.
16. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999; 40:1061-1071.
17. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001; 42:326-336.
18. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61:1781-1785.
19. 3 integrin related tumor imaging. Nucl Med Biol 2003; 30:1-9.
20. Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS, Radjopadhye M, Corstens FH, Boerman OC. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002; 17:641-646.
21. 3 integrin binding peptides in a nude mouse model. Cancer Res 2002; 62:6146-6151.
22. Van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt MA, Krenning EP, de Jong M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000; 90:186-198.
23. 3 integrin for tumor imaging. Bioconjug Chem 2002; 13:561-570.
24. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004; 31:179-189
25. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004; 31:11-19.
26. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2:214-221.
27. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40:539-551.
28. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002; 54: 459-476.
29. Wester HJ, Hamacher K, Stocklin G. A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol 1996; 23:365-372.
30. Kilbourn MR, Dence CS, Welch MJ, Mathias CJ. Fluorine-18 labeling of proteins. J Nucl Med 1987; 28:462-470.
31. 18F](fluoromethyl) benzoate. Appl Radiat Isot 1997; 48:169-173.
32. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998; 1:353-356.
33. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992; 9:249-304.
34. Brenner B, Rector F Jr. Brenner and Rector's: the kidney, 5th edn. Philadelphia: Saunders, 1996.
35. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238:491-497.
36. 3 integrin antagonists. J Med Chem 1999; 42:3033-3040.